Jacobs Levy Equity Management’s Gossamer Bio GOSS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$360K Buy
27,343
+6,154
+29% +$137K ﹤0.01% 866
2026
Q1
$557K Sell
21,189
-6,036
-22% -$759K ﹤0.01% 806
2025
Q4
$6.75M Buy
27,225
+9,624
+55% +$2.2M 0.03% 352
2025
Q3
$3.7M Buy
17,601
+3,956
+29% +$698K 0.01% 481
2025
Q2
$1.34M Buy
13,645
+10,117
+287% +$883K 0.01% 699
2025
Q1
$310K Sell
3,528
-15,655
-82% -$1.45M ﹤0.01% 974
2024
Q4
$1.39M Sell
19,183
-4,411
-19% -$302K ﹤0.01% 661
2024
Q3
$1.86M Buy
23,594
+5,536
+31% +$426K 0.01% 620
2024
Q2
$1.3M Sell
18,058
-2,368
-12% -$142K 0.01% 677
2024
Q1
$1.93M Sell
20,426
-5,862
-22% -$516K 0.01% 604
2023
Q4
$1.92M Buy
+26,288
New +$1.55M 0.01% 610
2022
Q2
– Sell
-7,656
Closed -$5.32M – 1034
2022
Q1
$5.32M Sell
7,656
-3,699
-33% -$2.85M 0.04% 405
2021
Q4
$10.3M Sell
11,355
-862
-7% -$819K 0.07% 298
2021
Q3
$12.3M Sell
12,217
-364
-3% -$268K 0.08% 261
2021
Q2
$8.17M Sell
12,581
-676
-5% -$469K 0.06% 337
2021
Q1
$9.8M Buy
13,257
+5,366
+68% +$4.33M 0.08% 297
2020
Q4
$6.1M Sell
7,891
-189
-2% -$149K 0.05% 362
2020
Q3
$8.02M Buy
8,080
+4,795
+146% +$5.09M 0.08% 254
2020
Q2
$3.42M Buy
3,285
+2,126
+183% +$2.14M 0.04% 422
2020
Q1
$941K Buy
1,159
+143
+14% +$149K 0.01% 639
2019
Q4
$1.27M Buy
+1,016
New +$1.64M 0.01% 639

Other funds holding GOSS

Jacobs Levy Equity Management's GOSS Position: Q2 2026 in Review

Jacobs Levy Equity Management increased its Gossamer Bio (GOSS) stake by 29% in Q2 2026, buying an estimated $137K and bringing the position to 27,343 shares worth $360K. The position accounts for ﹤0.01% of the portfolio, ranked #866.

Jacobs Levy Equity Management first reported a position in GOSS in Q4 2019 and has held it in 21 quarters since. The position peaked at $12.3M in Q3 2021. 166 funds tracked by Wall St. Rank hold GOSS as of Q2 2026.

  • Jacobs Levy Equity Management held 27,343 shares of Gossamer Bio worth $360K as of Q2 2026.
  • Jacobs Levy Equity Management bought 6,154 Gossamer Bio shares in Q2 2026, an estimated $137K.
  • Gossamer Bio made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #866 holding.
  • Jacobs Levy Equity Management first reported a position in Gossamer Bio in Q4 2019 and has held it in 21 quarters since.
  • Jacobs Levy Equity Management's Gossamer Bio position peaked at $12.3M in Q3 2021.
  • 166 funds tracked by Wall St. Rank held Gossamer Bio as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.